| Business Summary | | Transgene
SA
is
dedicated
to
the
discovery
and
development
of
gene
therapy
products
and
technologies
for
the
treatment
of
acquired
and
inherited
diseases.
The
Company
has
multiple,
proprietary
vector
platforms,
which
include
adenoviral,
vaccinia
viral,
retroviral,
cellular
and
synthetic
vectors.
The
Company
offers
multiple,
differentiated
vector
technologies
for
gene
delivery,
each
customized
for
different
clinical
situations.
Transgene
is
using
its
proprietary
vector
technology
to
create
a
broad
pipeline
of
potential
products
in
cancer,
cardiovascular
and
hereditary
diseases. | More
from
Market Guide: Expanded
Business Description |
| Financial Summary | | Transgene
is
an
integrated
biotechnology
company
dedicated
to
the
discovery
and
development
of
gene
therapy
technologies
and
products
for
the
treatment
of
acquired
or
inherited
diseases
for
which
there
is
no
cure
or
adequate
therapy.
For
the
six
months
ended
6/01,
revenues
fell
68%
to
EUR775K.
Net
loss
rose
7%
to
EUR11.1
million.
Revenues
reflect
decreased
grants
received
for
R
and
D.
Higher
loss
was
partially
offset
by
lower
S/G/A
costs
as
a
%
of
revenue. Recent Earnings Announcement For
the
3
months
ended
06/30/2001,
revenues
were
169;
after
tax
earnings
were
-5,528. (Preliminary; reported in thousands of Euro.) | More
from
Market Guide: Significant
Developments |
| Officers | |
| Position | Alain Merieux, 61 | Chiarman
of the Board | Gilles Belanger | CEO | Margaret Liu, M.D. | Vice
Chairman | Paul Bikard | CFO | Jean-Francois Carmier, 41 | Exec.
VP, Pharmaceutical Devel. |
| More
from
Market Guide on Officers & Directors: Expanded
List, Bios,
Compensation,
Options
|
|